Category: Markets
Published: 2026-07-16T11:29:35.000Z
Arbutus Biopharma and its licensee Genevant have filed three international lawsuits against Pfizer and BioNTech for patent infringement related to their LNP technology used in COVID-19 vaccines. Concurrently, Arbutus received approximately $178 million from Moderna as part of a settlement agreement and plans to return up to $230 million in capital to shareholders, commencing in Q3 2026. This action expands on their ongoing U.S. litigation against Pfizer/BioNTech.
News summary curated and translated by CausifyMarket. Always consult original sources before making any financial decision.